Clinical trial COBRIM
GO28141 A phase III, double-blind, placebo-controlled study of Vemurafenib versus Vemurafenib plus GDC-0973 in previously untreated BRAFV600-mutation positive patients with unresectable locally Advanced or metastatic melanoma
Cancers | |
---|---|
Organ | Skin |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Roche |
EudraCT Identifier | 2012-00300-811 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT01689519 |
Inclusion criteria | BRAF V600 mutation |
Last update |